Pellino play

How Bridge's first program attacks inflammatory disease on multiple fronts

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking first-in-class small molecules from academics, biotechs or pharmas in Asia.

Its first program, BBT-401, is an N-terminal lipidated 4aa peptide targeting pellino E3 ubiquitin protein ligase 1 (PELI1; pellino-1).

Bridge exclusively licensed IP covering BBT-401, its derivatives and therapeutic uses related to pellino-1 inhibition from Korea Research

Read the full 829 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE